Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

1 terminated/withdrawn out of 2 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
N/A
1(50.0%)
2Total
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT05841719Not ApplicableCompleted

Universal Capillary Screening for Chronic Autoimmune, Metabolic and Cardiovascular Diseases: Feasibility and Acceptability Pilot Study.

Role: lead

NCT04449380Phase 2Terminated

Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients

Role: lead

All 2 trials loaded